2012
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012, 118: 5463-5472. PMID: 22544643, PMCID: PMC3611659, DOI: 10.1002/cncr.27581.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2Triple-negative tumorsHR-positive/HER2-negative tumorsHER2-negative tumorsTriple-negative subtypePatterns of recurrenceEstrogen receptorProgesterone receptorClinicopathologic featuresBreast cancerNational Comprehensive Cancer Network centersNational Comprehensive Cancer NetworkHigher body mass indexEpidermal growth factor receptor 2Triple-negative breast cancerLymph node involvementComprehensive Cancer NetworkGrowth factor receptor 2Triple-negative cancersRisk of deathBody mass indexAbnormal screening mammogramBreast cancer subtypesHigher tumor classificationFactor receptor 2
2009
Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)
Lin N, Vanderplas A, Hughes M, Theriault R, Edge S, Wong Y, Blayney D, Niland J, Winer E, Weeks J. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal Of Clinical Oncology 2009, 27: 543-543. DOI: 10.1200/jco.2009.27.15_suppl.543.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkSite of recurrenceBreast cancer subtypesClinicopathological featuresProgesterone receptorEstrogen receptorStage ICancer subtypesInvasive ductal histologyExtensive intraductal componentComprehensive Cancer NetworkPatterns of recurrenceFuture clinical trialsMultiple breast cancer subtypesStandard immunohistochemical markersDuctal histologyLymphovascular invasionNode positivityIntraductal componentHER2 statusTN tumorsClinical trialsBreast cancerSubtype distributionImmunohistochemical markers
2006
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC, _ _. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal Of The National Comprehensive Cancer Network 2006, 4 Suppl 1: s1-26. PMID: 16507275, DOI: 10.6004/jnccn.2006.2001.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkBreast cancer treatment guidelinesCancer treatment guidelinesAdjuvant therapyBreast cancerTreatment guidelinesAdjuvant therapy recommendationsQuantitative estrogen receptorComprehensive Cancer NetworkEstrogen receptor levelsPositive breast cancerEndocrine therapyPostmenopausal womenMenopausal statusTask ForcePredictive factorsGuideline panelHER2 statusBiologic markersAromatase inhibitorsTherapy recommendationsReceptor levelsEstrogen receptorHER2/Cancer Network